ASTRANA HEALTH INC (ASTH)
Health Care · Managed Healthcare / Value-Based Care · NASDAQ
Astrana Health is a physician-centric, technology-enabled platform that manages care and operations for value-based healthcare providers serving Medicare and Medicaid patients.
What ASTRANA HEALTH INC does
Astrana Health is a healthcare delivery platform that operates through a network of affiliated medical groups and independent practice associations (IPAs). The company manages healthcare services primarily for government-sponsored programs, focusing on value-based care models, including the Medicare Shared Savings Program (MSSP) and various CMS innovation models like ACO REACH and ACO LEAD. Its operations encompass clinical care management, administrative support for physicians, and laboratory services.
Themes: value-based care, Medicare Advantage / Medicare programs, healthcare IT infrastructure, physician practice management
Fundamentals
- Price$38.11 as of 2026-08-24 close
- Market cap$2.1B as of 2026-08-24
- 1-year return+24.2% 2025-08-22 close $30.68 → 2026-08-24 close $38.11
- P/E60.49 as of 2026-08-25
- Net margin+0.9% as of 2026-08-25
- Gross margin+10.7% as of 2026-08-25
- ROE+3.9% as of 2026-08-25
- Debt / equity1.28 as of 2026-08-25
- Revenue growth (YoY)+56.7% as of 2026-08-25
- Revenue CAGR (3y)+40.6% SEC XBRL
- Beta1.02 as of 2026-08-25
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.1%; pays a dividend.
How ASTH compares in its sector
- price-to-earnings ratiotop 25% 193 covered Health Care peers, as of 2026-08-25
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-25
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-25
- gross marginbottom 10% 384 covered Health Care peers, as of 2026-08-25
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-25
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- indicated dividend yieldbottom 10% 71 covered Health Care peers, as of 2026-08-25
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ASTH is not currently in any published Top 10 list. Its scores are below.
Long-term score
47.2 #981 of 1,605 scored · #115 of 195 in Health Care
Growth 96th (revenue growth year over year 56.7%, 3-year revenue CAGR 40.6%) and long-term trend 50th (trading above its 200-day average); weakest is profitability (21st, operating margin 2.5%, return on equity 3.9%). Scored on 5 of 6 pillars — it pays a dividend, but its filings carry no per-share series to count increases from; no annual share count in its filings.
Short-term score
45.4 #954 of 1,698 scored · #162 of 236 in Health Care
Catalysts 61st: analysts have raised their average price target by 2.0% since the prior reading; setup 51st: over the past year its closes ranged, and it has retraced roughly a third of its move over the past year — 37% of it; weakest is volume and participation 31st: trading volume is about normal versus its 30-day average.
Scores as of 24 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, ASTH's dividend was covered by reported results (earnings payout 35%, free-cash-flow payout 8%). This describes past coverage, not a forecast.
- Earnings payout35% dividends / net income
- Free-cash-flow payout8% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How ASTRANA HEALTH INC looks technically
ASTRANA HEALTH INC (ASTH) is trading 23.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 77 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 7 trading days ago (its momentum flipped positive). It made a new 20-day low about 13 trading days ago. It is 26.1% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 23.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +23.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $41.16 | $41.16 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $30.80 | $30.80 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 44.93. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 77 trading days ago — a "golden cross", a bullish long-term signal | 77 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend) | 20.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30) | 47.1 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($33.92 to $41.00) — its "stochastic" reading is 59 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 59.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 7 trading days ago (its momentum flipped positive) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $51.60 | $51.60 |
|---|---|---|
| From the 52-week high | it is 26.1% below its 52-week high (its highest price of the past year) | -26.1% |
| Above the 52-week low | it is 110.8% above its 52-week low (its lowest price of the past year) | +110.8% |
| Below the 52-week high | it is 26.1% below its highest point of the past year | 26.1% |
| Since a 20-day breakout | it made a new 20-day low about 13 trading days ago | 13 sessions |
| Since a 55-day breakout | it made a new 55-day low about 13 trading days ago | 13 sessions |
| All-time high | its highest closing price on record is $133.23 (set on 2021-11-15) | $133.23 |
| Given back of the 52-week move | over the past year its closes ranged ($18.16 to $49.81), and it has given back roughly a third of its rise from last year’s low — 37% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $29.24 to $30.25. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 37.0% |
| From the all-time high | it is 71.4% below its all-time high | -71.4% |
| Nearest price level | it is trading 2.7% below a resistance level at $39.16 — a price it turned at twice since 2024-11-15, most recently on 2025-01-27. Since 2024-08-26 it has 12 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.7% |
| All-time low | its lowest closing price on record is $0.1 (set on 2009-07-20) | $0.1 |
| Above the all-time low | it is 38010.0% above its all-time low | +38,010% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 75% of it) | 25th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.03 between its high and its low — about 5.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.03 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $33.58 and $40.91 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $33.58 – $37.24 – $40.91 |
| Typical daily range (% of price) | its price moves about 5.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.3% |
| Stretch from the 200-day average | it is trading 3.6 daily ranges above its 200-day average price (23.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.69× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 2.0% since the prior reading | +2.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bearish engulfing | 9 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 9 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-24 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.4% |
|---|---|---|
| Gap filled | a 2.3% gap up opened on 2026-07-14 has been "filled" 29 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 29 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 8.8 percentage points (the stock lost 5.5% while the market gained 3.3%) | -8.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 1.7 percentage points (the stock gained 0.7% while the market gained 2.4%) | -1.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 87.2 percentage points (the stock gained 98.3% while the market gained 11.1%) | +87.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 5.9 percentage points (the stock gained 24.2% while the market gained 18.3%) | +5.9% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 10% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 7.0% of the share price. | -10.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 14% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $33.31 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +14.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% above the average price paid since it last reported on 2026-08-06 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $37.32 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +2.1% |
Price levels it has turned at before
ASTH last closed at $38.11 on 2026-08-24. Since 2024-08-26 it has turned at 12 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $39.16 | Resistance | 2.7% above the last close | turned there twice · 2024-11-15 to 2025-01-27 |
| $40.01 | Resistance | 5.0% above the last close | turned there three times · 2025-02-18 to 2026-06-11 |
| $34.97 | Support | 8.2% below the last close | turned there twice · 2025-02-06 to 2025-10-28 |
| $33.98 | Support | 10.8% below the last close | turned there four times · 2025-04-15 to 2026-08-06 |
| $32.25 | Support | 15.4% below the last close | turned there twice · 2025-03-18 to 2025-08-29 |
| $45.05 | Resistance | 18.2% above the last close | turned there twice · 2024-12-02 to 2026-07-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $44.93.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $37.71 and $41.95 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $33.92.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · Analyst price target recently RAISED · beating the market · Trading below the Ichimoku cloud · Elliott wave 4 pullbacks | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.40 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$51.50 range $41.00 – $65.00
Analyst estimates, as of 2026-08-25. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ASTH
- Consensus EPS estimate$0.86 next reporting period, as of 2026-08-25
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on CMS and state-sponsored programs for capitation payments","Regulatory and funding risks related to federal/state healthcare policy changes","Potential for cybersecurity breaches or disruptions to management information systems"]
What changed in the latest 10-Q
AI-assisted comparison of ASTH's 10-Q filed 2026-05-08 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references audited consolidated financial statements for year ended December 31, 2025, filed March 12, 2026 (vs. older filing referencing December 31, 2024, filed March 14, 2025)
- Newer filing describes Astrana as 'AI-powered' healthcare management company (vs. older filing describing 'technology-powered')
- Newer filing reports approximately 1.55 million patients as of March 31, 2026 (vs. older filing reporting over 1.6 million patients as of September 30, 2025)
- Newer filing includes regulatory discussion of CMS final 2027 Medicare Advantage and Part D payment rates issued April 6, 2026, noting modest increase and retention of 2024 risk adjustment model
- Newer filing includes detailed definition of Adjusted Net Income Attributable to Astrana and Adjusted EPS - Diluted as supplemental performance measures
- Newer filing includes Free Cash Flow as supplemental performance measure, defined as net cash from operating activities minus capital expenditures
- Newer filing reports management of 29 risk-bearing organizations as of March 31, 2026 (vs. older filing reporting 20 as of September 30, 2025)
- Newer filing financial statements compare three months ended March 31, 2026 vs. March 31, 2025 with specific revenue and expense metrics
- Newer filing adds 'other revenue primarily consisting of revenues earned from maternity care' to revenue description
- Removed:
- Older filing section 'Regulatory Trends' discussing One Big Beautiful Bill Act (OBBBA) signed July 4, 2025, with Medicaid work-requirement pilots and provider-tax changes, is not present in newer filing
- Older filing section 'Recent Developments' describing Prospect Medical Holdings acquisition completed July 1, 2025 for $674.9 million is not present in newer filing (though referenced in newer filing text)
- Older filing description of Operating Expenses including 'information technology equipment and software' is removed from newer filing
- Older filing Adjusted EBITDA definition referencing 'earnings before interest, taxes, depreciation, and amortization' changed wording in newer filing to 'earnings before interest expense, interest income, income taxes, depreciation, and amortization'
- Older filing financial statements comparing three months ended September 30, 2025 vs. September 30, 2024 are not present in newer filing
- Older filing nine months ended September 30, 2025 vs. 2024 financial data is not present in newer filing
- Reworded:
- Overview section: 'Astrana Health, Inc. ("Astrana") is a leading' changed to 'Astrana is a leading' in newer filing
- Overview patient description changed from 'we are responsible for coordinating care in value-based care arrangements for over 1.6 million patients' to 'we were responsible for coordinating the care for approximately 1.55 million patients'
- Overview patient description changed from 'comprised of managed care members' to 'are managed care members'
- Overview patient description changed from 'provide high-quality, cost-effective care' to 'deliver high-quality, cost-effective care'
- Revenue description: added 'generally on a monthly basis' to revenue recording period
- Adjusted EBITDA definition: 'earnings before interest, taxes, depreciation, and amortization' changed to 'earnings before interest expense, interest income, income taxes, depreciation, and amortization' in newer filing
- Section title changed from 'Regulatory Trends' in older filing to 'Regulatory and Industry Trends' in newer filing
- Notes:
- Newer filing appears truncated at 'The increase in revenue was partially attributable to the Prospect a' and does not include complete revenue discussion or nine-month comparison data present in older filing
- Comparison is between different quarterly periods (March 31, 2026 in newer vs. September 30, 2025 in older), which affects year-over-year metrics and patient count comparisons
- Older filing includes detailed nine-month financial data that is not present in the provided excerpt of newer filing due to truncation
Risk Factors
- Added:
- Added 'ACO LEAD' (ACO Long-Term Enhanced ACO Design) to the glossary (filed 2026-05-08)
- Added reference to 'ACO LEAD Model' in the CMS disclaimer statement (filed 2026-05-08)
- Added 'Adjusted EBITDA margin' and 'adjusted earnings per share (EPS) - diluted' and 'free cash flow' to forward-looking statement examples (filed 2026-05-08)
- Added reference to 'remediate the material weakness in our internal control over financial reporting' in forward-looking statements (filed 2026-05-08)
- Added reference to 'maintain effective internal control over financial reporting' in forward-looking statements (filed 2026-05-08)
- Removed:
- Removed 'ADSC' (Advanced Diagnostic and Surgical Center, Inc.) from the glossary (older filing 2025-11-10)
- Removed 'APC-LSMA' (APC-LSMA Designated Shareholder Medical Corporation) from the glossary (older filing 2025-11-10)
- Removed 'dispositions' from the list of forward-looking statement topics; narrowed to 'mergers' and 'acquisitions' only (newer filing 2026-05-08)
- Removed reference to 'our completed acquisition of certain businesses and assets of Prospect Medical Holdings, Inc.' and replaced with simplified 'any statements relating to our completed Prospect acquisition' (newer filing 2026-05-08)
- Reworded:
- Quarter ended date changed from 'September 30, 2025' to 'March 31, 2026' (newer filing 2026-05-08)
- CMS disclaimer changed from listing only 'ACO REACH Model' and 'MSSP' to also include 'ACO LEAD Model' (newer filing 2026-05-08)
- Sun Labs description changed from 'Sun Clinical Labs' to 'Sun Clinical Laboratories, a California corporation' (newer filing 2026-05-08)
- Form reference changed from 'this Form 10-Q' to 'this Quarterly Report on Form 10-Q' in forward-looking statements section (newer filing 2026-05-08)
- Annual Report reference year changed from 'December 31, 2024' with filing date 'March 14, 2025' to 'December 31, 2025' with filing date 'March 12, 2026' (newer filing 2026-05-08)
- Removed reference to 'those discussed in this Form 10-Q under the heading "Risk Factors" in Part II, Item 1A' from forward-looking statements (newer filing 2026-05-08)
- Notes:
- The newer filing text appears truncated at the end of the forward-looking statements section, limiting ability to assess full content changes
- Item numbering format changed between filings (newer uses 'ITEM' in caps, older uses 'Item'), but page numbers differ (newer shows pages 49-53, older shows pages 67-70), making direct structural comparison difficult
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for ASTH — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 2 matched disclosures for ASTH from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding ASTH as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 8,459,107
- Reported value $207,417,318
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ASTH had 2,827,451 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ASTH had 5.07% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.93 days to cover at the same settlement.
- Reported short interest (shares) 2,827,451
- Short interest (% of shares outstanding) 5.07%
- Prior settlement (shares) 2,679,220
- Reported change 5.53%
- Days to cover (reported) 4.93
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Elevance Health (ELV)
- Centene (CNC)
- Humana (HUM)
- UnitedHealth Group (UNH)
- Agilon Health (AGL)
- Privia Health (PRVA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ASTH vs…
Frequently asked questions
What does ASTRANA HEALTH INC (ASTH) do?
Astrana Health is a healthcare delivery platform that operates through a network of affiliated medical groups and independent practice associations (IPAs). The company manages healthcare services primarily for government-sponsored programs, focusing on value-based care models, including the Medicare Shared Savings Program (MSSP) and various CMS innovation models like ACO REACH and ACO LEAD.
What sector is ASTRANA HEALTH INC (ASTH) in?
ASTRANA HEALTH INC (ASTH) is classified in the Health Care sector. Its industry is Managed Healthcare / Value-Based Care. It trades on NASDAQ.
Does ASTH pay a dividend?
Yes — ASTRANA HEALTH INC (ASTH) pays a dividend, with an indicated yield of about 0.14% (market data, as of 2026-08-25). Informational only — not financial advice.
Who are ASTRANA HEALTH INC's (ASTH) competitors?
Notable peers of ASTRANA HEALTH INC (ASTH) include Elevance Health, Centene, Humana, UnitedHealth Group and Agilon Health. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in ASTH?
Yes — we hold 2 matched STOCK Act disclosures for ASTH from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is ASTRANA HEALTH INC (ASTH) overbought or oversold right now?
ASTRANA HEALTH INC (ASTH) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 47, in the neutral middle (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ASTH come from?
Fundamentals and prices come from market data, as of 2026-08-25; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-25. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.